Today before the opening
bell, Actinium Pharmaceuticals reported that it had closed its final tranche of
approximately $3,310,860. That brought the company’s total gross proceeds to
$6,636,720 million from the private placement of common stock and warrants to
new and existing accredited investors. In addition, the total offering amount
of the company’s securities sold to investors underwent an increase to
$6,636,700 from $6,600,000 to cover overallotments.
The primary use of these
proceeds will be used to fund further development of Iomab TM-B and Actimab-A.
In the words of the company, Iomab TM-B is a “bone marrow conditioning agent
for preparing patients for hematopoietic stem cell transplantation” in Phase 3
clinical development, and Actimab-A is the company’s “lead drug candidate in
multicenter Phase 1/2 trials in Acute Myeloid Leukemia.”
“This funding gives us
additional capital to prepare for the pivotal trial Phase 3 trial of Iomab TM-B
as a potentially curative treatment regimen for elderly AML patients preparing
for a bone marrow transplant,” said Kaushik J. Dave, President and CEO of
Actinium Pharmaceuticals. “In addition, we will continue the Phase 1/2 proof of
concept trial of Actimab-B as an induction therapy for elderly AML. Both Iomab
TM-B and Actimab-A address areas of cancer treatment where there are no
FDA-approved medications.”
In the offering of common
stock and warrants, the company sold around 1,106,120 shares of common stock at
$6.00 per share and issued 276,529 five-year warrants that are actionable at
$9.00 per share. A FINRA-registered broker dealer, Laidlaw & Co. (UK) Ltd.
served as the offering’s exclusive placement agent.
For more information about
Actinium Pharmaceuticals, visit: www.actiniumpharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
